TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14656279

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 172

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 172

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 172
Study: 10847421

Group type: EXPERIMENTAL
Intervention: Dalteparin (50, 100, and 200 U/kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Enoxaparin (0.5, 1.0, and 2.0 mg/kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Dalteparin and Enoxaparin (therapeutic equivalent doses)
Number of subjects: 6
Study: 9029666

Group type: EXPERIMENTAL
Intervention: Amineptine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 1825799

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (administered according to two schedules: early at birth, 3 months, and 6 months; later at 3 months, 4.5 months, and 6 months)
Number of subjects: 1989

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (unscheduled administration)
Number of subjects: 1989

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine
Number of subjects: 1989

Group type: COMPARATOR
Intervention: Poliomyelitis vaccine
Number of subjects: 1989
Study: 6299161

Group type: EXPERIMENTAL
Intervention: Mass closure technique
Number of subjects: 1129

Group type: COMPARATOR
Intervention: Polyglycolic acid
Number of subjects: 1129

Group type: COMPARATOR
Intervention: Monofilament nylon
Number of subjects: 1129
Study: 31074022

Group type: EXPERIMENTAL
Intervention: Random forest classifier model using top 50 important radiomics features
Number of subjects: 118
Study: 28791447

Group type: EXPERIMENTAL
Intervention: Active pulsed magnetic stimulation (PMS)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham pulsed magnetic stimulation
Number of subjects: 120

Group type: COMPARATOR
Intervention: No active pulsed magnetic stimulation
Number of subjects: 120
Study: 27418815

Group type: EXPERIMENTAL
Intervention: Glycopyrronium (GLY) 50 μg
Number of subjects: 126

Group type: COMPARATOR
Intervention: Tiotropium (TIO) 18 μg
Number of subjects: 126
Study: 25088746

Group type: EXPERIMENTAL
Intervention: Increased plasma levels of very long chain ceramide species
Number of subjects: 497

Group type: COMPARATOR
Intervention: Normal albuminuria
Number of subjects: 497

Group type: COMPARATOR
Intervention: Microalbuminuria
Number of subjects: 497

Group type: COMPARATOR
Intervention: Macroalbuminuria
Number of subjects: 497
Study: 23285923

Group type: EXPERIMENTAL
Intervention: Phentolaminum group
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate-phentolaminum group
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Anisodamine-phentolaminum group
Number of subjects: 360

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 360
Study: 19863842

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 807

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 807

Group type: EXPERIMENTAL
Intervention: Latent trajectory mixture models
Number of subjects: 807

Group type: COMPARATOR
Intervention: Drop-out control
Number of subjects: 807
Study: 18165405

Group type: EXPERIMENTAL
Intervention: Vestibulectomy
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Biofeedback
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 51

Group type: COMPARATOR
Intervention: All treatments (Vestibulectomy, Biofeedback, Cognitive-behavioral therapy)
Number of subjects: 51
Study: 16124946

Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg
Number of subjects: 28
Study: 12457076

Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 0
Study: 11152036

Group type: EXPERIMENTAL
Intervention: Written questionnaire
Number of subjects: 700

Group type: COMPARATOR
Intervention: Standardised face-to-face interview
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Both methods (questionnaire and interview)
Number of subjects: 700
Study: 9404089

Group type: EXPERIMENTAL
Intervention: Monitor group (drastic cleaning every three weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (insufficient cleaning)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Monitor group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 8504436

Group type: COMPARATOR
Intervention: Intravenous 4-aminopyridine (4-AP)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Oral 4-aminopyridine (4-AP) at maximum daily dosage of 0.5 mg/kg body weight, three times a day for 12 weeks
Number of subjects: 70
Study: 3323291

Group type: EXPERIMENTAL
Intervention: i.v. pulsatile Gn‐RH at 2.5 micrograms/90 min (A; no. = 10)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: i.v. pulsatile Gn‐RH at 5 micrograms/90 min (B; no. = 13)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: i.v. pulsatile Gn‐RH at 10-12.5 micrograms/90 min (C; no. = 3)
Number of subjects: 10
Study: 31047650

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) in ED
Number of subjects: 252

Group type: COMPARATOR
Intervention: Standard of Care (SOC) in ED
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) in Pathology
Number of subjects: 252

Group type: COMPARATOR
Intervention: Standard of Care (SOC) in Pathology
Number of subjects: 252
Study: 29103847

Group type: EXPERIMENTAL
Intervention: Left Atrial Appendage Closure (LAAC) with Watchman device
Number of subjects: 1114

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 1114

Group type: EXPERIMENTAL
Intervention: LAAC
Number of subjects: 1114
Study: 26420970

Group type: EXPERIMENTAL
Intervention: Sequential therapy (rabeprazole 20 mg and amoxicillin 1 g twice daily for 5 days, followed by rabeprazole 20 mg, clarithromycin 500 mg and metronidazole 500 mg twice daily for 5 days)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Hybrid therapy (rabeprazole 20 mg and amoxicillin 1 g for 7 days, followed by rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg twice daily for 7 days)
Number of subjects: 175
Study: 23713295

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 60
Study: 21708034

Group type: EXPERIMENTAL
Intervention: Methylsulfonylmethane (MSM) 1.125 grams 3 times daily for 12 weeks
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo 3 times daily for 12 weeks
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Methylsulfonylmethane (MSM)
Number of subjects: 49
Study: 18048863

Group type: EXPERIMENTAL
Intervention: Recombinant tissue-type plasminogen activator
Number of subjects: 40
Study: 16817081

Group type: EXPERIMENTAL
Intervention: Ethacridine lactate (10 ml per gestational week, max 200 ml)
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Misoprostol (200 microg intravaginally, followed by 100 microg oral every 4 hours for 24 hours)
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Ethacridine lactate + Oxytocin (initial 6 mU/min, additional 6 mU/min every 20 min)
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Misoprostol + Oxytocin (administered similarly to group III)
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Oxytocin with misoprostol
Number of subjects: 388

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 388
Study: 12946886

Group type: EXPERIMENTAL
Intervention: QIDS-SR(16)
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: IDS-SR(30)
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: HAM-D(24)
Number of subjects: 596
Study: 11302109

Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg daily
Number of subjects: 4271

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 4271
Study: 9449936

Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 8363165

Group type: EXPERIMENTAL
Intervention: Modified-fat (vegetable oil) mozzarella cheese product
Number of subjects: 26

Group type: COMPARATOR
Intervention: Skim-milk mozzarella cheese
Number of subjects: 26
Study: 31697817

Group type: EXPERIMENTAL
Intervention: Prophylactic platelet transfusion threshold of 25 × 10^9/L
Number of subjects: 653

Group type: COMPARATOR
Intervention: Prophylactic platelet transfusion threshold of 50 × 10^9/L
Number of subjects: 653
Study: 30269148

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Healthy Controls
Number of subjects: 51
Study: 27072860

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25191666

Group type: EXPERIMENTAL
Intervention: Adper Single Bond (SB) with cariogenic challenge (pH)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (SE) with cariogenic challenge (pH)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Adper Single Bond (SB) with sound enamel (S)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Clearfil SE Bond (SE) with sound enamel (S)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (C) groups
Number of subjects: 80

Group type: COMPARATOR
Intervention: Permanent groups (PERM)
Number of subjects: 80
Study: 21994233

Group type: EXPERIMENTAL
Intervention: Infliximab plus methotrexate (5 mg/kg at weeks 0, 2, 6, and 14 plus 15 mg/week methotrexate)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Infliximab plus methotrexate
Number of subjects: 115

Group type: COMPARATOR
Intervention: Methotrexate alone (15 mg/week)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Methotrexate alone
Number of subjects: 115
Study: 21161650

Group type: EXPERIMENTAL
Intervention: Simultaneous bilateral tubeless PCNL
Number of subjects: 99

Group type: COMPARATOR
Intervention: Staged tubeless PCNL
Number of subjects: 99
Study: 17561989

Group type: EXPERIMENTAL
Intervention: Drotrecogin alpha activated
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15583700

Group type: EXPERIMENTAL
Intervention: sibutramine (10 mg/day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 80
Study: 12397571

Group type: EXPERIMENTAL
Intervention: Asthma history in IDCM cases
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Asthma duration in IDCM cases
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Beta-agonist use
Number of subjects: 197

Group type: COMPARATOR
Intervention: Control group asthma history
Number of subjects: 197
Study: 10534551

Group type: EXPERIMENTAL
Intervention: iloprost (1 ng/kg/min in 6 h i.v. infusion, for 5 consecutive days, 1 week per month)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: low-dose oral cyclosporin A (2.5 mg/kg/day) associated with iloprost
Number of subjects: 20
Study: 7567390

Group type: EXPERIMENTAL
Intervention: Auditory radio interference during training sessions for 4 weeks, 3 hours per week.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interference training condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard training
Number of subjects: 0
Study: 2141289

Group type: EXPERIMENTAL
Intervention: Orchiectomy plus dexamethasone 0.5 mg in the morning and 0.3 mg at night
Number of subjects: 60

Group type: COMPARATOR
Intervention: Orchiectomy plus cyproterone acetate 100 mg 3 times per day
Number of subjects: 60
Study: 484522

Group type: EXPERIMENTAL
Intervention: Pyridoxine 2 mg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Pyridoxine 100 mg
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Pyridoxine 100 mg (retreatment)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Measurements of flexion and pinch strength
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Electromyography
Number of subjects: 22
Study: 31570495

Group type: EXPERIMENTAL
Intervention: Programmed intermittent bolus (PIB) delivery of local anesthetic (10 mL of ropivacaine 0.2% every 2 hours)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Continuous infusion (CI) (5 mL/hour) of local anesthetic
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both CI and PIB regimens
Number of subjects: 60
Study: 30373650

Group type: EXPERIMENTAL
Intervention: aPDT with Bixa orellana extract and LED light (Valo Cordless Ultradent®)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Tongue scraping
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Combination of tongue scraping and aPDT with Bixa orellana extract
Number of subjects: 39
Study: 26488941

Group type: EXPERIMENTAL
Intervention: Human chorionic gonadotropin (HCG)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Testosterone (T) - transdermal
Number of subjects: 40

Group type: COMPARATOR
Intervention: Testosterone (T) - undecaonate
Number of subjects: 40

Group type: COMPARATOR
Intervention: Testosterone (T) - enantate
Number of subjects: 40
Study: 24500111

Group type: EXPERIMENTAL
Intervention: β-alanine (BA) supplementation (6.4 g day(‐1)) for 4 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 40
Study: 23151451

Group type: EXPERIMENTAL
Intervention: MuStDO5 DNA vaccine with 500 μg of each plasmid and escalating doses of hGM-CSF (0, 20, 100 or 500 μg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 32
Study: 19570108

Group type: EXPERIMENTAL
Intervention: Antipsychotics
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Mood stabilizers
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Combinations of antipsychotics and mood stabilizers
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 33
Study: 17666974

Group type: EXPERIMENTAL
Intervention: Experimental breast cancer treatment
Number of subjects: 58
Study: 15083253

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Oral methylphenidate
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 11668222

Group type: EXPERIMENTAL
Intervention: Pravastatin (n = 25)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo (n = 26)
Number of subjects: 51
Study: 9839991

Group type: EXPERIMENTAL
Intervention: Hybrid neural network technique for segmenting and classifying dynamic contrast-enhanced MR images
Number of subjects: 0
Study: 7528868

Group type: EXPERIMENTAL
Intervention: Multimedia (MM) presentation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paper-based text (Text) presentation
Number of subjects: 0
Study: 2517282

Group type: EXPERIMENTAL
Intervention: Adjuvant portal infusion (5‐Fluorouracil 500 mg/m2/d x 7 continuous infusion + Mitomycin‐C 10 mg/m2 on day 1 as a bolus injection)
Number of subjects: 533

Group type: COMPARATOR
Intervention: Radical surgery alone (control group)
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Full-dose adjuvant chemotherapy (among 195 patients, 85%)
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Adjuvant treatment (overall)
Number of subjects: 533
Study: 1166982

Group type: EXPERIMENTAL
Intervention: Warfarin (daily doses for 21 days)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Warfarin plus rifampin (600 mg a day orally for the last 10 days)
Number of subjects: 8
Study: 31556537

Group type: EXPERIMENTAL
Intervention: Naloxone nasal spray 2 mg (20 mg/ml)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Intravenous naloxone 1 mg
Number of subjects: 5
Study: 27865116

Group type: EXPERIMENTAL
Intervention: Minnesota Living with Heart Failure Questionnaire (MLHF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: EQ‐5D‐3L
Number of subjects: 0
Study: 27255750

Group type: EXPERIMENTAL
Intervention: Intervention group (clinicians received electronically measured adherence report)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (clinicians did not receive adherence report)
Number of subjects: 100
Study: 25052792

Group type: EXPERIMENTAL
Intervention: Ecstasy-related stimuli
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control stimuli
Number of subjects: 240
Study: 22424843

Group type: EXPERIMENTAL
Intervention: Adalimumab (Group I, n=8) administered from post-operative day 14
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Adalimumab (Group II, n=15) administered at 6 months post-operatively after confirmation of endoscopic recurrence despite treatment with azathioprine, infliximab, or 5-ASA
Number of subjects: 23
Study: 19416298

Group type: EXPERIMENTAL
Intervention: PCT-guided treatment
Number of subjects: 223

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: PCT-guided treatment in COPD subgroup
Number of subjects: 223

Group type: COMPARATOR
Intervention: Standard treatment in COPD subgroup
Number of subjects: 223
Study: 17554216

Group type: EXPERIMENTAL
Intervention: HIV-1 replication capacity (RC) adjusted by baseline CD4 cell counts, HIV-1 RNA levels, and phenotypic susceptibility
Number of subjects: 139

Group type: COMPARATOR
Intervention: HIV-1 replication capacity (RC) < or = 65%
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: HIV-1 replication capacity (RC) > 65%
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: HIV-1 replication capacity (RC) on a log10 basis
Number of subjects: 139
Study: 17206943

Group type: EXPERIMENTAL
Intervention: budesonide 6 mg and ursodeoxycholic acid 15 mg/kg
Number of subjects: 77

Group type: COMPARATOR
Intervention: ursodeoxycholic acid alone
Number of subjects: 77
Study: 12447868

Group type: EXPERIMENTAL
Intervention: IFN-alpha treatment
Number of subjects: 109

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 109
Study: 10326847

Group type: EXPERIMENTAL
Intervention: Tacrolimus (FK506)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Cyclosporine (CSA)
Number of subjects: 35
Study: 8607150

Group type: EXPERIMENTAL
Intervention: rHuEPO (600 U/kg)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 204
Study: 1910019

Group type: EXPERIMENTAL
Intervention: Nitroglycerin ointment placed on arm
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Nitroglycerin ointment placed on chest
Number of subjects: 26
Study: 6351663

Group type: EXPERIMENTAL
Intervention: 30 mg Mr 1268
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 30 mg pentazocine
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 31974081

Group type: EXPERIMENTAL
Intervention: Intravenous alteplase under current local resources
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Intravenous alteplase under assumed ideal conditions
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Endovascular therapy plus intravenous alteplase under assumed ideal conditions
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Interventional neuroradiologists' decision to refrain from intravenous alteplase under assumed ideal conditions
Number of subjects: 607
Study: 30179728

Group type: EXPERIMENTAL
Intervention: Criticism
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Warm comments
Number of subjects: 97

Group type: COMPARATOR
Intervention: Neutral comments
Number of subjects: 97
Study: 28081827

Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 24902

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 24902

Group type: COMPARATOR
Intervention: GPI use
Number of subjects: 24902
Study: 25887932

Group type: EXPERIMENTAL
Intervention: Hydros (hyaluronan-based hydrogel suspended in hyaluronan solution)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Hydros-TA (HA plus 10 mg of triamcinolone acetonide)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Synvisc-One (hylan G-F 20)
Number of subjects: 98
Study: 24075893

Group type: EXPERIMENTAL
Intervention: γ-T-rich supplementation (500 mg γ-T/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 30
Study: 21839707

Group type: EXPERIMENTAL
Intervention: Elimination diet (without cow's milk and derivatives, wheat, egg, tomato, and chocolate) for 4 weeks
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Fecal ECP assay
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Fecal tryptase assay
Number of subjects: 160
Study: 19619148

Group type: EXPERIMENTAL
Intervention: Botox (20 I.E. diluted in 0.5 mL saline)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo (0.5 mL saline)
Number of subjects: 64
Study: 17784794

Group type: EXPERIMENTAL
Intervention: Experiments with student attrition
Number of subjects: 35

Group type: COMPARATOR
Intervention: Experiments without student attrition
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Overall attrition rates
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Differential attrition rates
Number of subjects: 35
Study: 15005715

Group type: EXPERIMENTAL
Intervention: C516T 5HT2A gene polymorphism
Number of subjects: 79

Group type: COMPARATOR
Intervention: COMT gene polymorphisms
Number of subjects: 79

Group type: COMPARATOR
Intervention: 5HTTLPR gene polymorphisms
Number of subjects: 79

Group type: COMPARATOR
Intervention: T102C 5HT2A gene polymorphisms
Number of subjects: 79
Study: 11437759

Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 40
Study: 9579877

Group type: EXPERIMENTAL
Intervention: Horse antilymphocyte globulin (HALG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rabbit antithymocyte globulin (RATG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phytohaemagglutinin (PHA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: T cell supernatants with recombinant human GM-CSF (rhGM-CSF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: T cell supernatants without growth factor
Number of subjects: 0
Study: 7921346

Group type: EXPERIMENTAL
Intervention: Intravenous alcohol infusion (0.5 g ethanol per kg body weight in 15 minutes)
Number of subjects: 12
Study: 2662037

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1 g elemental calcium for 5 days)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 18
Study: 31960275

Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (250 mg magnesium oxide) for 8 weeks
Number of subjects: 60
Study: 31722151

Group type: EXPERIMENTAL
Intervention: Smartwatch-based irregular pulse notification algorithm
Number of subjects: 419297